Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMH6NG5)

Drug Name
FENDILINE Drug Info
Synonyms
fendiline; Fendilin; 13042-18-7; Fendilinum; Fendilinum [INN-Latin]; Fendilina [INN-Spanish]; Fendiline [INN]; EINECS 235-915-6; CHEMBL254832; Fendiline (INN); Benzenepropanamine, gamma-phenyl-N-(1-phenylethyl)-; Benzenepropanamine, .gamma.-phenyl-N-(1-phenylethyl)-; 3,3-diphenyl-N-(1-phenylethyl)propan-1-amine; Phendilin; Fendilina; Senzit; NCGC00018223-06; SPBio_001131; Spectrum_000443; AC1L1FPB; Spectrum5_001302; Spectrum2_001006; Prestwick1_000270; Spectrum4_000417; Prestwick3_000270; Spectrum3_001436; Prestwick2_000270
Cross-matching ID
PubChem CID
3336
ChEBI ID
CHEMBL254832
CAS Number
CAS 13042-18-7
TTD Drug ID
D02FEA
VARIDT Drug ID
DR00949
INTEDE Drug ID
DR0686

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Steroid biosynthesis 2.32 0.00e+0 19/20 (95%) FDFT1;SQLE;DHCR24;...
ECM-receptor interaction 1.96 9.84e-3 80/88 (90.91%) SPP1;FN1;LAMC2;...
Sphingolipid metabolism 1.94 6.56e-3 32/49 (65.31%) UGCG;GALC;ASAH1;...
Fatty acid biosynthesis 1.82 2.71e-2 16/18 (88.89%) FASN;ACACA;ACSL3;...
Lysosome 1.80 2.76e-2 115/128 (89.84%) GALC;ASAH1;LIPA;...
Other glycan degradation 1.76 3.28e-2 13/18 (72.22%) MAN2C1;GLB1;NEU1;...
Biosynthesis of unsaturated fatty acids 1.74 4.36e-2 21/27 (77.78%) TECR;SCD;FADS1;...
Ether lipid metabolism 1.72 4.18e-2 32/49 (65.31%) PLAAT3;PLA2G2A;LPCAT1;...
Glycerolipid metabolism 1.71 4.15e-2 44/61 (72.13%) LIPG;AKR1B10;LPIN1;...
Terpenoid backbone biosynthesis 1.69 4.82e-2 18/22 (81.82%) HMGCS1;IDI1;FDPS;...
Other types of O-glycan biosynthesis 1.67 4.76e-2 29/47 (61.7%) ST6GAL1;C1GALT1;GALNT10;...
Autoimmune thyroid disease -1.69 4.75e-2 46/53 (86.79%) FAS;IL2;HLA-DOA;...
Proteasome -1.72 3.56e-2 44/46 (95.65%) PSMB6;PSMB1;PSMA7;...
Allograft rejection -1.75 3.20e-2 32/38 (84.21%) CD40;FAS;IL2;...
Systemic lupus erythematosus -1.79 2.72e-2 45/135 (33.33%) ELANE;HLA-DOA;HLA-DQB1;...
Parkinson disease -1.79 3.26e-2 176/249 (70.68%) MAPK8;DRD1;ERN1;...
RNA transport -1.80 3.56e-2 128/186 (68.82%) MAGOH;NXT2;RANBP2;...
Graft-versus-host disease -1.87 2.72e-2 32/42 (76.19%) KLRD1;FAS;IL2;...
Type I diabetes mellitus -2.04 0.00e+0 38/43 (88.37%) FAS;IL2;HLA-DOA;...
Ribosome -2.15 0.00e+0 113/158 (71.52%) RPS10;RPL6;MRPS18C;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 1.11uM - 10uM 24H
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 1.11uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
MDA-MB-468 CVCL_0419 Homo sapiens 1.11uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 1.11uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SNU-407 CVCL_5004 Homo sapiens 1.11uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 1.11uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 1.11uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CJM CVCL_U797 Homo sapiens 3.33uM - 10uM 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHH-5 CVCL_1320 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 1.11uM - 10uM 24H
HCC95 CVCL_1276 Homo sapiens 1.11uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H2110 CVCL_1529 Homo sapiens 1.11uM - 10uM 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 1.11uM - 10uM 24H
Ovary
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 1.11uM - 10uM 24H
PC-3 CVCL_0035 Homo sapiens 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
IGR-37 CVCL_1303 Homo sapiens 1.11uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 1.11uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 1.11uM - 10uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 1.11uM - 10uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 1.11uM - 10uM 24H